Special thanks to Greg Czarnota for this story.
Congratulations to Patrick Cheung, UT DRO assistant professor, who has been awarded industry funding for his proposal “Stereotactic Radiotherapy for Oligo-Progression in Kidney Cancer Patients on 1st Line Sunitinib Therapy: A Phase II Study” with funding of near $1M.
This will be a multi-centre phase II study conducted in Canada to look at the role of SBRT in delaying the need to change systemic therapy in patients who develop oligo-progression while on Sutent. In essence it is exploring a new way of using radiotherapy in the management of metastatic cancer in conjunction with systemic therapy.
Special thanks from his team to Dr. Bjarnason who was instrumental in getting this investigator initiated grant approved by Pfizer.